RNA USA

RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines in the wake of the COVID-19 pandemic.

But huge advances are also being made in RNAi and antisense technologies. Our understanding of RNA chemistry continues to mature. Delivery tools are increasingly sophisticated and impactful.

Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules is emerging.

With that in mind, we can’t wait to bring the community together, face-to-face, for the RNA Leaders USA Congress.

Brett Monia

CEO

Ionis Pharmaceuticals

Frank de Rosa

Chief Technology Officer & Global Head of Research, mRNA Center of Excellence

Sanofi

Lucio Iannone

VP of Venture Investments Health

Leaps at Bayer

Lovisa Afzelius

CEO, Alltrna

Origination Partner, Flagship Pioneering

Peter Smith

CEO

Remix Therapeutics

Matt Disney

Professor, Department of Chemistry

Scripps Research

Dietrich Stephan

Chairman and Chief Executive Officer

NeuBase Therapeutics

Karen Chapman

CSO

Eclipsebio

Samuel Wickline

CSO

Altamira Therapeutics

Hans-Peter Vornlocher

Managing Director, Research

LGC Axolabs

Katarina Stenklo

Enterprise Solutions Commercial Activation Leader

Cytiva

Jeremy Little

Director, Custom Oligonucleotides

Chemgenes

Venue

Centrally located and exquisitely appointed in the iconic Back Bay neighborhood, The Colonnade Hotel in Boston MA is a contemporary luxury hotel.

Take a look

Programme

Keynote panels, keynote presentations, panel sessions and plenty of networking time built in. See the program of RNA Leaders.

Partnering

Our state-of-the-art app-based 1-2-1 partnering system allows you to schedule, move and confirm meetings ‘on the fly’.

What Our Attendees Say

"One of the best conferences I have attended."

Dietrich A. Stephan, Ph.D
Chairman, Founder and CEO, Neubase Therapeutics

"Top-class attendance and remarkable organization."

Solène Guilliot
Director of Clinical Development and Medical Affairs, Medesis Pharma

"Highly relevant talks and panel discussions."

Marie Wikstrom Lindholm
SVP, Head of Molecular Design, Silence Therapeutics

"A fantastic environment to discuss the RNA world."

Tamara Martinez
R+D Manager, Sylentis

"High quality meeting and extremely valuable networking."

Matthew Wood
Professor of Neuroscience, University of Oxford

SCIENTIFIC, CLINICAL AND COMMERCIAL DEVELOPMENT OF RNA THERAPEUTICS AND VACCINES

Created by

A new paradigm for disease prevention

1-2-1 Partnering

RNA Leaders speakers